NCT00083187View on ClinicalTrials.gov

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

August 31, 2008

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

hydroxyurea

DRUG

laromustine

Trial Locations (5)

13273

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27710

Duke Comprehensive Cancer Center, Durham

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

SE5 8RX

King's College Hospital, London

Sponsors
All Listed Sponsors
lead

Vion Pharmaceuticals

INDUSTRY

NCT00083187 - VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia | Biotech Hunter | Biotech Hunter